IL-13–associated epithelial remodeling correlates with clinical severity in nasal polyposis - 04/05/23
Abstract |
Background |
Epithelial remodeling is a histopathologic feature of chronic inflammatory airway diseases including chronic rhinosinusitis (CRS). Cell-type shifts and their relationship to CRS endotypes and severity are incompletely described.
Objective |
We sought to understand the relationship of epithelial cell remodeling to inflammatory endotypes and disease outcomes in CRS.
Methods |
Using cell-type transcriptional signatures derived from epithelial single-cell sequencing, we analyzed bulk RNA-sequencing data from sinus epithelial brushings obtained from patients with CRS with and without nasal polyps in comparison to healthy controls.
Results |
The airway epithelium in nasal polyposis displayed increased tuft cell transcripts and decreased ciliated cell transcripts along with an IL-13 activation signature. In contrast, CRS without polyps showed an IL-17 activation signature. IL-13 activation scores were associated with increased tuft cell, goblet cell, and mast cell scores and decreased ciliated cell scores. Furthermore, the IL-13 score was strongly associated with a previously reported activated (“polyp”) tuft cell score and a prostaglandin E2 activation signature. The Lund-Mackay score, a computed tomographic metric of sinus opacification, correlated positively with activated tuft cell, mast cell, prostaglandin E2, and IL-13 signatures and negatively with ciliated cell transcriptional signatures.
Conclusions |
These results demonstrate that cell-type alterations and prostaglandin E2 stimulation are key components of IL-13–induced epithelial remodeling in nasal polyposis, whereas IL-17 signaling is more prominent in CRS without polyps, and that clinical severity correlates with the degree of IL-13–driven epithelial remodeling.
Il testo completo di questo articolo è disponibile in PDF.Graphical abstract |
Key words : Chronic rhinosinusitis, nasal polyposis, type 2 inflammation, endotype, IL-13, prostaglandin E2, epithelial remodeling
Abbreviations used : CRS, CRSsNP, CRSwNP, LM, PGE2, scSeq, UCSF
Mappa
This work was supported by the National Institutes of Health (grant no. 5R01AI136962 to E.D.G.; grant nos. R01HL128439, R01HL135156, and P01HL132821 to M.A.S.; grant nos. F32HL140868 and T32HL007185 to M.E.K.; and grant no. F32HL158174 to C.A.S.), the Department of Defense (M.A.S.), the A.P. Giannini Foundation (M.E.K.), the Webb-Waring Early Career Investigator Award from the Boettcher Foundation (C.M.M.), the Nina Ireland Program for Lung Health at UCSF (E.D.G. and M.E.K.), the UCSF John A. Watson Faculty Scholar Fund (J.G.G.), and the SABRE Center at UCSF (E.D.G.). |
|
Disclosure of potential conflict of interest: J. G. Gurrola II is a Genentech Advisory Board Consultant with agreement ending December 2021. A. N. Goldberg is a minor stock holder in Siesta Medical. S. D. Pletcher and A. N. Goldberg are coinventors of patent 14/394, 006 Sinus diagnostics and treatments. The rest of the authors declare that they have no relevant conflicts of interests. |
Vol 151 - N° 5
P. 1277-1285 - Maggio 2023 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?